Structure Therapeutics Inc (GPCR)

$56.50 -1.23 (-2.13%)
Market Cap 4.08B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 883,100
Avg Vol 1,020,430
Day's Range N/A - N/A
Shares Out 70.64M
Stochastic %K 6%
Beta -1.80
Analysts Strong Sell
Price Target $108.93

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in pre...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
Flying_Trader2
Flying_Trader2 Mar. 6 at 6:49 PM
$VKTX hum, maybe NVO flew their plane from SFO to SD. $GPCR is dn and VK is up.
0 · Reply
Astondb9
Astondb9 Mar. 6 at 4:34 PM
$VKTX I warned Kylie $GPCR formed an inverse cup on March 3rd. It is now crashing while vktx is holding . I said if it loses 58, youre toast. He is now toast.
1 · Reply
Twitgb
Twitgb Mar. 5 at 4:52 PM
$GPCR hey kyle, have you mentioned head and shoulders? thanks for the idea, it is working like a charm. 50's now. thanks for the chart.
0 · Reply
Twitgb
Twitgb Mar. 5 at 4:19 PM
$GPCR anybody seen kyle? Is he ok? Or falling down with gpcr? poor little guy.
0 · Reply
Quantumup
Quantumup Mar. 4 at 7:22 PM
Truist reiterated $VKTX Buy/$75, and said, We hosted VKTX mgmnt for NDR. LLY $NVO $GPCR Truist added—The mood was upbeat as VK2735 was riding high on a winning combo of GLP+GIP as demonstrated by the recent REDEFINE4 toplined by NOVO. In this backdrop, mgmnt is executing on ongoing and forthcoming Ph3 programs for both SQ & oral VK2735. Offering of SQ and oral as well as monthly maintenance regimen of VK2735 could offer a comprehensive "closed-loop obesity ecosystem" with a commercial edge. Bottom line, VKTX is marching towards what could very well be the most consequential data readout in the obesity pipeline over the next 12 to 18 months. We encourage investors to revisit the story as we see near-term catalysts for the stock. Reit BUY.
0 · Reply
BlondeAmbition
BlondeAmbition Mar. 4 at 6:18 PM
$AVXL $VKTX $GPCR
0 · Reply
Twitgb
Twitgb Mar. 4 at 6:15 PM
$GPCR like head and shoulders style load? lol
1 · Reply
JonathanV
JonathanV Mar. 4 at 4:42 PM
$GPCR Q: what does the imminent 44-wk data need to look like for shares to go meaningfully higher or lower
0 · Reply
Kylenorth
Kylenorth Mar. 4 at 2:43 PM
$GPCR road to 100!!
1 · Reply
biolover
biolover Mar. 4 at 2:02 PM
$GPCR $VKTX don’t let Bourla and Metsera deal convince u against u conviction. It doesn’t matter what bio funds do. As far I see they are big in companies with lousy drugs ( I do not want to name any here but believe me I know there are lousy) .. there are a lot of reasons for any pharma to be hesitant before pulling the trigger on GPCR . Even the most idiot managements.
0 · Reply
Latest News on GPCR
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Feb 26, 2026, 4:02 PM EST - 11 days ago

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Feb 18, 2026, 4:51 PM EST - 19 days ago

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 4 weeks ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN LLY NVO PFE VKTX

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Jan 21, 2026, 10:05 AM EST - 6 weeks ago

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 7 weeks ago

Structure CEO Ray Stevens talks its obesity drug portfolio

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Dec 11, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Dec 9, 2025, 11:15 PM EST - 3 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Dec 9, 2025, 8:30 AM EST - 3 months ago

Structure Therapeutics: Phase 2b Puts Aleniglipron In The Oral GLP-1 Top Tier (Rating Upgrade)

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Dec 8, 2025, 7:27 PM EST - 3 months ago

Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Dec 8, 2025, 5:18 PM EST - 3 months ago

Structure: Maintaining Strong Buy As Aleniglipron Succeeds In Obesity Study Program

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Dec 8, 2025, 4:01 PM EST - 3 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Dec 8, 2025, 12:46 PM EST - 3 months ago

Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Dec 8, 2025, 11:20 AM EST - 3 months ago

Structure Therapeutics stock: what's driving sudden 103% jump in GPCR shares?

Structure's experimental pill shows 11% weight loss in study, shares up

Dec 8, 2025, 8:14 AM EST - 3 months ago

Structure's experimental pill shows 11% weight loss in study, shares up

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Dec 8, 2025, 8:00 AM EST - 3 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Dec 7, 2025, 6:20 PM EST - 3 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 4 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 6, 2025, 4:01 PM EST - 4 months ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 4 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 10, 2025, 1:54 PM EDT - 6 months ago

Structure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 4:01 PM EDT - 7 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 9 months ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN LLY NVO PFE REGN VKTX XBI

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

Jun 20, 2025, 7:30 PM EDT - 9 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Apr 14, 2025, 10:49 AM EDT - 11 months ago

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

VKTX

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI INSM MRK SWTX

Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments

Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Mar 20, 2025, 9:28 AM EDT - 1 year ago

Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Jan 30, 2025, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

Jan 6, 2025, 2:53 PM EST - 1 year ago

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst

VKTX

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Dec 17, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Structure CEO on the competitive landscape for oral GLP-1 drugs

Dec 5, 2024, 6:17 PM EST - 1 year ago

Structure CEO on the competitive landscape for oral GLP-1 drugs

NVO

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Nov 15, 2024, 8:30 AM EST - 1 year ago

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Nov 13, 2024, 4:01 PM EST - 1 year ago

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Oct 22, 2024, 2:07 PM EDT - 1 year ago

Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D.

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

Aug 26, 2024, 12:00 PM EDT - 1 year ago

Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say

AMGN CRBP SRRK VKTX

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Aug 23, 2024, 3:17 PM EDT - 1 year ago

Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field

Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 1 year ago

Structure Therapeutics CEO on GLP drugs

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Jun 7, 2024, 4:05 PM EDT - 1 year ago

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Jun 5, 2024, 7:53 PM EDT - 1 year ago

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Jun 3, 2024, 6:27 PM EDT - 1 year ago

Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Jun 3, 2024, 4:09 PM EDT - 1 year ago

Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants

Structure Therapeutics reports promising weight-loss drug data

Jun 3, 2024, 2:38 PM EDT - 1 year ago

Structure Therapeutics reports promising weight-loss drug data

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Jun 3, 2024, 8:42 AM EDT - 1 year ago

Structure Therapeutics' stock jumps on weight-loss-pill trial results

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Jun 3, 2024, 7:30 AM EDT - 1 year ago

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

May 7, 2024, 11:33 AM EDT - 1 year ago

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

AMGN LLY NVO ALT AZN VKTX

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Apr 16, 2024, 7:09 PM EDT - 2 years ago

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

AMGN AZN LLY NVO PFE SNY VKTX

Flying_Trader2
Flying_Trader2 Mar. 6 at 6:49 PM
$VKTX hum, maybe NVO flew their plane from SFO to SD. $GPCR is dn and VK is up.
0 · Reply
Astondb9
Astondb9 Mar. 6 at 4:34 PM
$VKTX I warned Kylie $GPCR formed an inverse cup on March 3rd. It is now crashing while vktx is holding . I said if it loses 58, youre toast. He is now toast.
1 · Reply
Twitgb
Twitgb Mar. 5 at 4:52 PM
$GPCR hey kyle, have you mentioned head and shoulders? thanks for the idea, it is working like a charm. 50's now. thanks for the chart.
0 · Reply
Twitgb
Twitgb Mar. 5 at 4:19 PM
$GPCR anybody seen kyle? Is he ok? Or falling down with gpcr? poor little guy.
0 · Reply
Quantumup
Quantumup Mar. 4 at 7:22 PM
Truist reiterated $VKTX Buy/$75, and said, We hosted VKTX mgmnt for NDR. LLY $NVO $GPCR Truist added—The mood was upbeat as VK2735 was riding high on a winning combo of GLP+GIP as demonstrated by the recent REDEFINE4 toplined by NOVO. In this backdrop, mgmnt is executing on ongoing and forthcoming Ph3 programs for both SQ & oral VK2735. Offering of SQ and oral as well as monthly maintenance regimen of VK2735 could offer a comprehensive "closed-loop obesity ecosystem" with a commercial edge. Bottom line, VKTX is marching towards what could very well be the most consequential data readout in the obesity pipeline over the next 12 to 18 months. We encourage investors to revisit the story as we see near-term catalysts for the stock. Reit BUY.
0 · Reply
BlondeAmbition
BlondeAmbition Mar. 4 at 6:18 PM
$AVXL $VKTX $GPCR
0 · Reply
Twitgb
Twitgb Mar. 4 at 6:15 PM
$GPCR like head and shoulders style load? lol
1 · Reply
JonathanV
JonathanV Mar. 4 at 4:42 PM
$GPCR Q: what does the imminent 44-wk data need to look like for shares to go meaningfully higher or lower
0 · Reply
Kylenorth
Kylenorth Mar. 4 at 2:43 PM
$GPCR road to 100!!
1 · Reply
biolover
biolover Mar. 4 at 2:02 PM
$GPCR $VKTX don’t let Bourla and Metsera deal convince u against u conviction. It doesn’t matter what bio funds do. As far I see they are big in companies with lousy drugs ( I do not want to name any here but believe me I know there are lousy) .. there are a lot of reasons for any pharma to be hesitant before pulling the trigger on GPCR . Even the most idiot managements.
0 · Reply
whiskyqueen
whiskyqueen Mar. 4 at 1:09 PM
$VKTX Will be the final and also the largest metabolic acquisition on record. Don’t be confused/surprised if $GPCR were to get bought before us….Always the best for last 😉
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 4 at 5:36 AM
$GPCR Current Stock Price: $63.02 Contracts to trade: $62.5 GPCR Mar 20 2026 Call Entry: $2.50 Exit: $3.17 ROI: 27% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Kylenorth
Kylenorth Mar. 3 at 6:50 PM
$GPCR PAY ME!
0 · Reply
BlondeAmbition
BlondeAmbition Mar. 3 at 6:01 PM
$GPCR $VKTX
2 · Reply
Kylenorth
Kylenorth Mar. 3 at 3:43 PM
$GPCR easy money!! bo coming soon
1 · Reply
Kylenorth
Kylenorth Mar. 3 at 3:19 PM
$GPCR LOAD THE BOAT HERE!! IN FOR CALLS
0 · Reply
BlondeAmbition
BlondeAmbition Mar. 3 at 2:50 AM
$GPCR $VKTK Gonna get some underdog👍
0 · Reply
judgeyoung2
judgeyoung2 Mar. 2 at 8:21 PM
$GPCR at support. the 44 week data is imminent. buyout candidate. let’s see.
1 · Reply
Kylenorth
Kylenorth Mar. 2 at 3:05 PM
$GPCR time to start loading again!
0 · Reply
IamCharlieSheen
IamCharlieSheen Mar. 2 at 2:13 PM
$GPCR head and should or rebound area? we will soon find out w possible M& A activity not sure I would want to short here but looks enticing
0 · Reply
Quantumup
Quantumup Mar. 2 at 12:23 PM
H.C. Wainwright⬆️ $GPCR's PT to $114 from $90 and reiterated at a Buy rating. $VKTX $LLY $NVO $MBX AZN AMGN RHHBY PFE Here's what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2028443691505914151?s=20
0 · Reply
Theflash88
Theflash88 Feb. 27 at 9:31 PM
$GPCR Chasing out the weak hands..
0 · Reply